Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.

Generalized nonsegmental vitiligo is often associated with the activation of melanocyte-specific autoimmunity. Because chemokines play an important role in the maintenance of immune responses, we examined chemotactic signatures in cultured vitiligo melanocytes and skin samples of early (≤2 months) and advanced (≥6 months) vitiligo. Analysis showed that melanocytes in early lesions have altered expression of several chemotaxis-associated molecules, including elevated secretion of CXCL12 and CCL5. Higher levels of these chemokines coincided with prominent infiltration of the skin with antigen presenting cells (APCs) and T cells. Most of the intralesional APCs expressed the CD86 maturation marker and co-localized with T cells, particularly in early vitiligo lesions. These observations were confirmed by in vivo animal studies showing preferential recruitment of APCs and T cells to CXCL12- and CCL5-expressing transplanted melanocytes, immunotargeting of the chemokine-positive cells, continuous loss of the pigment-producing cells from the epidermis, and development of vitiligo-like lesions. Taken together, our studies show that melanocyte-derived CXCL12 and CCL5 support APC and T-cell recruitment, antigen acquisition, and T-cell activation in early vitiligo and reinforce the role of melanocyte-derived CXCL12 and CCL5 in activation of melanocyte-specific immunity and suggest inhibition of these chemotactic axes as a strategy for vitiligo stabilization.

[1]  A. Offidani,et al.  CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept , 2007, The British journal of dermatology.

[2]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[3]  R. Boissy,et al.  A role for tyrosinase-related protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes: Implications for vitiligo. , 2006, The American journal of pathology.

[4]  Koichiro Nakamura,et al.  Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. , 2003, The Journal of allergy and clinical immunology.

[5]  J. Cyster,et al.  Leukocyte migration: Scent of the T zone , 2000, Current Biology.

[6]  U. Kisa,et al.  Increased tumor necrosis factor alpha (TNF‐α) and interleukin 1 alpha (IL1‐α) levels in the lesional skin of patients with nonsegmental vitiligo , 2006 .

[7]  J. Vestbo,et al.  CD8 chemokine receptors in chronic obstructive pulmonary disease , 2008, Clinical and experimental immunology.

[8]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[9]  N. J. Gibbons,et al.  Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. , 2004, The Journal of investigative dermatology.

[10]  D. Bani,et al.  Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. , 2009, Histology and histopathology.

[11]  J. Hanna,et al.  Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. , 2003, Blood.

[12]  S. Nishikawa,et al.  Murine Cutaneous Mastocytosis and Epidermal Melanocytosis Induced by Keratinocyte Expression of Transgenic Stem Cell Factor , 1998, The Journal of experimental medicine.

[13]  D. Bennett,et al.  A line of non‐tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth , 1987, International journal of cancer.

[14]  H. Kolb,et al.  Expression and Secretion of RANTES (CCL5) in Human Adipocytes in Response to Immunological Stimuli and Hypoxia , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[15]  R. M. van den Wijngaard,et al.  A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. , 2001, Trends in immunology.

[16]  T. Bieber,et al.  IP10/CXCL10 - CXCR3 interaction: a potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus. , 2007, Acta dermato-venereologica.

[17]  M. Juan,et al.  One-tube-PCR technique for CCL2, CCL3, CCL4 and CCL5 applied to fine needle aspiration biopsies shows different profiles in autoimmune and non-autoimmune thyroid disorders , 2006, Journal of endocrinological investigation.

[18]  H. Mitsui,et al.  CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis , 2013, The Journal of investigative dermatology.

[19]  V. Sehgal,et al.  Vitiligo: Auto‐immunity and immune responses , 2006, International journal of dermatology.

[20]  Y. Abiko,et al.  Expression profile of chemokines and chemokine receptors in epithelial cell layers of oral lichen planus. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[21]  C. Brosnan,et al.  Regulation of RANTES/CCL5 expression in human astrocytes by interleukin‐1 and interferon‐β , 2004, Journal of neurochemistry.

[22]  M. Namazi Statins: novel additions to the dermatologic arsenal? , 2004, Experimental dermatology.

[23]  J. V. Stein,et al.  Chemokine control of lymphocyte trafficking: a general overview , 2005, Immunology.

[24]  Ido D. Weiss,et al.  Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. , 2006, The Journal of investigative dermatology.

[25]  P. Ghezzi,et al.  Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. , 1991, Cytokine.

[26]  M. Shigemori,et al.  Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. , 2009, International journal of oncology.

[27]  M. Picardo,et al.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference , 2012, Pigment cell & melanoma research.

[28]  S. Woo,et al.  Distinct locomotive patterns of granulocytes, monocytes and lymphocytes in a stable concentration gradient of chemokines , 2008, International journal of laboratory hematology.

[29]  N. J. Gibbons,et al.  Methionine sulfoxide reductases A and B are deactivated by hydrogen peroxide (H2O2) in the epidermis of patients with vitiligo. , 2008, The Journal of investigative dermatology.

[30]  S. Orlow,et al.  Vitiligo inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8 , 2012, The Journal of investigative dermatology.

[31]  S. Meller,et al.  Socioeconomic factors in lupus erythematosus. , 2005, Autoimmunity reviews.

[32]  C. Hunter,et al.  CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo , 2014, Science Translational Medicine.

[33]  R. Spritz Modern vitiligo genetics sheds new light on an ancient disease , 2013, The Journal of dermatology.

[34]  K. Yoon,et al.  Gene correction by RNA-DNA oligonucleotides. , 2000, Pigment cell research.

[35]  G. Babcock,et al.  PIG3V, an immortalized human vitiligo melanocyte cell line, expresses dilated endoplasmic reticulum , 2000, In Vitro Cellular & Developmental Biology - Animal.

[36]  V. Alexeev,et al.  Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. , 2006, The Journal of investigative dermatology.

[37]  R. Steinman,et al.  Expression of a Functional Eotaxin (CC Chemokine Ligand 11) Receptor CCR3 by Human Dendritic Cells1 2 3 , 2002, The Journal of Immunology.

[38]  L. Juliano,et al.  Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice , 2008, Journal of Neuroinflammation.

[39]  G. Nilsson,et al.  Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. , 2002, Biochemical and biophysical research communications.

[40]  O. Igoucheva,et al.  Chemokine-enhanced DNA vaccination in cancer immunotherapy , 2013, Oncoimmunology.

[41]  O. Igoucheva,et al.  Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication , 2007, Molecular Cancer Therapeutics.